Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
Volume 1.50M
Average 2.02M
NMRA Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$146.66M, compared with -$125.92M a year earlier.
Context
- Net debt amounted to 95.3% of total assets at the end of Q1 FY2026, up 46.3 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -16.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (182.05M) USD
- Year-over-year change
- -29.8%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (182.05M) | -29.8% |
| FY2024 | 2024-12-31 | (140.3M) | +62.0% |
| FY2023 | 2023-12-31 | (368.81M) | -58.6% |
| FY2022 | 2022-12-31 | (232.5M) | +42.9% |
| FY2021 | 2021-12-31 | (407.2M) | — |
Net Debt vs competitors
How NMRA compares with its peers on the latest reported figures
- NMRA's Mar 2026 net debt of -$146.66M is the 8th highest of the 10 companies compared; the peer median is -$50.97M.
- Its year-over-year change of -16.5% is the 5th highest of 10, against a peer median of -24.8%.
- Net debt amounts to 95.3% of total assets for NMRA, versus a peer median of 12.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $308.73M | -24.8% | -11.5% | 107.9% | |
| Mar 2026 | $19.62M | -54.8% | +46.1% | 7.3% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | -$27.28M | +75.9% | — | 4.9% |
| Mar 2026 | -$44.39M | -30.3% | — | 12.8% | |
| Mar 2026 | -$50.97M | -123.7% | — | 9.7% | |
| Mar 2026 | -$51.95M | +52.6% | — | 10.1% | |
| Mar 2026 | -$114.34M | -144.8% | — | 39.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | -$146.66M | -16.5% | — | 95.3% |
| Mar 2026 | -$321.81M | +21.1% | — | 92.0% | |
| Mar 2026 | -$544.14M | +30.6% | — | 83.4% | |
| Peer median (excluding NMRA) | -$50.97M | -24.8% | +17.3% | 12.8% | |
Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 409.25M | 240.94M | 374.04M | 142.15M | 182.53M |
| Short-term Investments | 0 | 130.94M | 79.94M | 165.43M | 0 |
| Net Receivables | 200K | 919K | 939K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 125K | 50K | 0 | 6.48M | 8.01M |
| Total Current Assets | 415.6M | 387.96M | 478.28M | 314.06M | 190.54M |
| Property, Plant & Equipment (Net) | 4.04M | 10.64M | 6.86M | 2.92M | 457K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 23.51M | 9.85M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 9.65M | 4.13M | 1.21M | 0 | 53K |
| Total Non-current Assets | 13.69M | 38.28M | 17.92M | 2.92M | 510K |
| Total Assets | 429.3M | 426.23M | 496.2M | 316.97M | 191.05M |
| Account Payables | 1.64M | 7.15M | 337K | 3.31M | 3.38M |
| Short-term Debt | 0 | 0 | 0 | 0 | 284K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 8.13M | 10.04M | 10.15M | 10.11M | 28.79M |
| Total Current Liabilities | 23.28M | 23.7M | 25.11M | 29.89M | 32.45M |
| Long-term Debt | 0 | 0 | 0 | 0 | 193K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 730.24M | 844.32M | 155K | 22K | 54.53M |
| Total Non-current Liabilities | 731.24M | 849.39M | 2.01M | 22K | 54.73M |
| Total Liabilities | 754.52M | 873.08M | 27.12M | 29.91M | 87.18M |
| Common Stock | 3K | 3K | 16K | 16K | 17K |
| Retained Earnings | (336.61M) | (467.51M) | (703.43M) | (947.22M) | (1.18B) |
| Accumulated OCI | 0 | (774K) | (76K) | 62K | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (325.22M) | (446.85M) | 469.08M | 287.06M | 103.87M |
| Total Debt | 2.05M | 8.44M | 5.23M | 1.85M | 477K |
| Net Debt | (407.2M) | (232.5M) | (368.81M) | (140.3M) | (182.05M) |
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.